drugset
drugset / Trial / NCT03493191

A Single Dose Study of SHR0410 in Healthy Male Participants

NCT03493191 ↗

Phase 1 Completed 48 enrolled Atridia Pty Ltd. Linear Clinical Research · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, single ascending-dose study to investigate the effect of a single intravenous (IV) dose of SHR0410 at 6 dose levels (0.5 μg/kg, 1 μg/kg, 2 μg/kg, 5 μg/kg, 10 μg/kg and 20 μg/kg) in healthy participants.

Timeline

Start
2018-04-15
Primary completion
2018-06-29
Completion
2018-07-14

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR0410 Unknown 0.5 ug/kg Intravenous
Subject SHR0410 Unknown 1 ug/kg Intravenous
Subject SHR0410 Unknown 2 ug/kg Intravenous
Subject SHR0410 Unknown 5 ug/kg Intravenous
Subject SHR0410 Unknown 10 ug/kg Intravenous
Subject SHR0410 Unknown 20 ug/kg Intravenous

Indications

No indication recorded.